Back to home
DEALS & FUNDINGApril 6, 2026·4 min read
Ginkgo Bioworks Signs Three New Pharma Partnerships for Cell Line Engineering
The synthetic biology platform expands its pharmaceutical footprint, applying its cell programming platform to optimize CHO cell lines for biologics manufacturing and engineer microbial strains for complex natural product synthesis.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.